The proliferative activity of bone marrow blasts was determined in 19 patients with acute leukemia during early induction therapy using in vitro tritiated thymidine (3H-TdR) cytoautoradiography and propidium iodide DNA flow cytofluorometry. Folloding 1-3 causes of treatment, the aliquot of bone marrow blasts in 9 patients, who later achieved remission or marrow aplasia, was reduced to a greater extent that of the remaining 10 patients who failed to respond. In the first group of patients, the 3H-TdR labeling index was increased by 259-653 % over the pretreatment value, whereas it was lower than 104 % of the pretreatment value in all but one unresponsive patient. Leukemic blast recruitment is conceivable. It might have facilitated remission by increasing the effectiveness of the antileukemic agents administered later.
Get full access to this article
View all access options for this article.
References
1.
AgliettaM., CollyL.: Relevance of recruitment-synchronization in the scheduling of 1-β-D arabino-furanosylcytosine in a slow-growing acute myeloid leukemic of the rat.Cancer Res., 39: 2727–2732, 1979.
2.
AlbertD.S., DurieB.G.M., SalmonS.E.: Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics.Cancer Treat. Rep., 61: 381–388, 1977.
3.
AmadoriS., PettiM.C., De FrancescoA., Chieri-chiniA., MastrovincenzoC., TestaM.G., MandelliF.: Lack of prognostic significance of the pretreatment labeling and mitotic indices of the marrow blasts in acute non-lymphatic leukemia.Cancer, 41: 1154–1160, 1978.
4.
BennetJ.M., KatovskyD., DanielN.T., FlandrinG., GaltonD.A.G., GralnickM.R., SultanC.: Proposals for the classification of the acute leukemias.Br. J. Haematol., 33: 451–458, 1976.
5.
BurkeP.J., KarpJ.E., BraineH.G., VaughanW.P.: Timed sequential therapy of human leukemia based upon the response of leukemic cells to humoral growth factors.Cancer Res., 37: 2138–2146, 1977.
6.
BurkeP.J., VaughanW.P., KarpJ.E.: A rationale for sequential high-dose chemotherapy of leukemia timed to coincide with induced tumor proliferation.Blood, 55: 960–968, 1980.
7.
FailleA., NajeanJ., BernardJ.: Capacité de proliferation des cellules leucemiques de la moelle humaine.Nouv. Press Med., 2: 889–894, 1973.
8.
FriedJ.: Method for quantitative evaluation of data from flow microfluorometry.Comput. Biomed. Res., 9: 263–276, 1976.
9.
HartS.J., GeorgeL.S., FreiE.III, BodeyG.P., NickersonR.C., FreireichJ.: Prognostic significance of pretreatment proliferative activity in adult acute leukemia.Cancer, 39: 1606–1617, 1977.
10.
HayesF.A., GreenA.A., MauerA.M.: Correlation of cell kinetic and clinical response to chemotherapy in disseminated neuroblastoma.Cancer Res., 37: 3766–3770, 1977.
11.
HewlettJ.S., BattleJ.D., BishopS.C., FowlerW.M., SchwartzS.O., HagenP.S., LouisS.: Phase II - study of A-8103 (NSC 25154) in acute leukemia in adults.Cancer Chemother. Rep., 42: 25–28, 1964.
12.
HiddemanW., BüchnerJ., AndreefM., WormannB., MelamedM.R., ClarksonB.D.: Cell kinetics in acute leukemia. A critical reevaluation based on new data.Cancer, 50: 250–258, 1982.
13.
IslamA., CatovskyD., GaltonD.A.G.: Histological study of bone marrow regeneration following chemotherapy for acute myeloid leukaemia in blast transformation.Br. J. Haematol., 45: 535–540, 1980.
14.
KarpJ.E., HumphreyR.L., BurkeJ.P.: Timed sequential chemotherapy in refractory multiple myeloma with cytoxan and adriamycin based on induced tumor proliferation.Blood, 57: 468–475, 1981.
15.
LampkinB.C., NagaoT., MauerA.M., FlessaH.C., HokD.A., FisherV.: Manipulation of the mitotic cycle in the treatment of acute myelogenous leukemia.Br. J. Haematol., 32: 29–40, 1976.
16.
MontecuccoC.M., RiccardiA., TraversiE., GiordanoP., MazziniG., AscariE.: Proliferative activity of bone marrow cells in primary dysmyelo-poietic (preleukemic) syndromes.Cancer, 52: 1190–1195, 1983.
17.
MurphyS.B., AurR.J.A., SimoneJ.V., GeorgeS., MauerA.M.: Pretreatment cytokinetic studies in 94 children with acute leukemia: relationship to other variables at diagnosis and to outcome of standard treatment.Blood, 49: 683–691, 1977.
18.
MurphyS.B., DahlG.V., GeorgeS.L., J'KarasJ., LookA.T., SimoneJ.V., MauerA.M.: Determination of the significance of in vitro blast cell [3H] thymidine labeling indices obtained initially and serially during induction therapy of acute-non-lymphocytic leukemia.Leukemia Res., 6: 639–648, 1982.
19.
PaiettaE., MittermayerK., SchwerzmeierJ.: Proliferation kinetics and cyclic AMP as prognostic factors in adult acute leukemia.Cancer, 46: 102–108, 1980.
20.
PileriA., BarnengoM.G., BoccadoroM., ConteP.F., MarinoneC., MaseraP.: Early recruitment in the human myeloma cell population after cytostatic treatment.Haematologica, 61: 184–193, 1976.
21.
RiccardiA., MartinottiA., PeruginiS.: Cytokinetic changes in two cases of plasma cell leukemia treated with a multipeptide derivative of m-[di(2-chloroethyl)amino]-L-phenylalanine (peptichemio).Eur. J. Cancer, 14: 1099–1106, 1978.
22.
RiccardiA., MazziniG., MontecuccoC.M., CresciR., TraversiE., BerzuiniC., AscariE.: Sequential vincristine, arabinosylcytosine and adryamicin in acute leukemia: cytologic and cytokinetic studies.Cytometry, 3: 104–109, 1982.
23.
SalmonS.E.: Expansion of the growth fraction in multiple myeloma with alkylating agents.Blood, 45: 119–129, 1975.
24.
SchabelF.M.Jr.: The use of tumor growth kinetics in planning « curative » chemotherapy of advanced solid tumors.Cancer Res., 29: 2384–2389, 1969.
25.
TyrerD.D., KlineI., VendittiJ.M., GoldinA.: Separate and sequential chemotherapy of mouse leukemia L1210 with l-β-D-arabinofuranosylcyto-sine hydrochloride and 1,3-bis(2-chloroethyl)-l-ni-trosourea.Cancer Res., 27: 873–879, 1976.
26.
VaughanW.P., KarpJ.E., BurkeP.J.: Long chemotherapy free remission time after single cycle timed sequential chemotherapy for acute myelocytic leukemia.Cancer, 45: 859–865, 1980.
